Assessment of the Effectiveness of the Thalidomide Celgene Pregnancy Prevention Programme (PPP) in the United Kingdom

被引：0
|
作者：
Witty, J. M.
Thompson, M.
Freeman, J. [1 ]
Bwire, R. [1 ]
机构：
[1] Celgene Corp, Summit, NJ USA
来源：
DRUG SAFETY | 2010年 / 33卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
19
引用
收藏
页码：901 / 901
页数：1
相关论文
共 48 条
  • [41] Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom
    Kindred, Max
    Shabrina, Zahratu
    Zakiyah, Neily
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (01) : 49 - 60
  • [42] Assessment of the population-level effectiveness of the Avahan HIV-prevention programme in South India: a preplanned, causal-pathway-based modelling analysis
    Pickles, Michael
    Boily, Marie-Claude
    Vickerman, Peter
    Lowndes, Catherine M.
    Moses, Stephen
    Blanchard, James F.
    Deering, Kathleen N.
    Bradley, Janet
    Ramesh, Banadakoppa M.
    Washington, Reynold
    Adhikary, Rajatashuvra
    Mainkar, Mandar
    Paranjape, Ramesh S.
    Alary, Michel
    LANCET GLOBAL HEALTH, 2013, 1 (05): : E289 - E299
  • [43] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom
    M. F. Botteman
    M. Meijboom
    I. Foley
    J. M. Stephens
    Y. M. Chen
    S. Kaura
    The European Journal of Health Economics, 2011, 12 : 575 - 588
  • [44] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: Comparison between France, Germany, and the United Kingdom
    Botteman, M. F.
    Kaura, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom
    Botteman, M. F.
    Meijboom, M.
    Foley, I.
    Stephens, J. M.
    Chen, Y. M.
    Kaura, S.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (06): : 575 - 588
  • [46] Recruitment patterns in multicentre randomised trials fit more closely to Price's Law than the Pareto Principle: A review of trials funded and published by the United Kingdom Health Technology Assessment Programme
    Knowlson, Catherine
    Dean, Alexandra
    Doherty, Laura
    Fairhurst, Caroline
    Brealey, Stephen
    Torgerson, David J.
    CONTEMPORARY CLINICAL TRIALS, 2022, 113
  • [47] COMPARATIVE RISK ASSESSMENT OF FUTURE HEALTH, COST-EFFECTIVENESS AND EQUITY OUTCOMES OF THE UK SOFT DRINKS INDUSTRY LEVY AND THE NHS DIABETES PREVENTION PROGRAMME: A MICROSIMULATION MODELLING STUDY
    Soiland-Reyes, Claudia
    O'Flaherty, Martin
    Chen, Tao
    Collins, Brendan
    Kypridemos, Christodoulos
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2022, 76 : A6 - A6
  • [48] Comparison of cost-effectiveness of POM (prescription only) statins; OTC (over the counter) statin and plant sterol/stanol products for primary CVD (cardiovascular disease) prevention in the United Kingdom from the patient's perspective
    Amirsadri-Naeini, M.
    Jackson, P. R.
    VALUE IN HEALTH, 2008, 11 (03) : A198 - A198
12345